LobbyingSkyhawk Therapeutics lobbying by quarter
Skyhawk Therapeutics's latest lobbying report covers Q2 2026, at $90K. The four quarters Q4 2025–Q3 2026 total $210K. Its first report covers Q1 2024; the issues it reports most are Taxation/Internal Revenue Code and Health Issues.
Skyhawk Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $210K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2024 | $30K | 1 |
| Q2 2024 | $20K | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $30K | 1 |
| Q1 2026 | $90K | 1 |
| Q2 2026 | $90K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$180K · 2 reports
- Taxation$80K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES5 reports
- SENATE5 reports
Firms it paid
| Firm | ||
|---|---|---|
| FGS Global | $260K | 6 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/16for Q2 | FGS Global | $90K |
| 04/14for Q1 | FGS Global | $90K |
| 01/20for Q4 2025 | FGS Global | $30K |
| 25/10/23for Q4 2025 | FGS Global | Under $5,000 |
| 24/10/17for Q3 2024 | FGS Global | Under $5,000 |
| 24/07/17for Q2 2024 | FGS Global | $20K |
| 24/04/22for Q1 2024 | FGS Global | $30K |
| 24/03/28for Q1 2024 | FGS Global | Under $5,000 |